Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Average Recommendation of “Hold” from Brokerages

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been given a consensus rating of “Hold” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.3333.

AYTU has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Finally, Ascendiant Capital Markets increased their price objective on shares of Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Daytona Street Capital LLC purchased a new stake in Aytu BioPharma during the fourth quarter valued at $26,000. Rothschild Wealth LLC purchased a new position in Aytu BioPharma in the fourth quarter worth about $52,000. Dimensional Fund Advisors LP bought a new stake in shares of Aytu BioPharma during the 3rd quarter valued at about $58,000. Bellevue Asset Management LLC bought a new stake in shares of Aytu BioPharma during the 4th quarter valued at about $65,000. Finally, XTX Topco Ltd purchased a new stake in shares of Aytu BioPharma during the 4th quarter valued at about $67,000. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

AYTU stock opened at $2.64 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. The firm has a 50 day moving average price of $2.53 and a 200-day moving average price of $2.35. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $3.07. The firm has a market capitalization of $28.33 million, a price-to-earnings ratio of -0.69 and a beta of 0.35.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.The company had revenue of $15.17 million during the quarter, compared to analysts’ expectations of $12.17 million.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.